For Q3 FY2026 ended March 31, 2026, Benitec Biopharma reported no revenue and a net loss of $11.9 million, an improvement of 17.7% year-over-year. Operating loss was $13.6 million, improving 11.4% from the prior year. Diluted EPS was -$0.24, a 36.8% improvement. The company held $184.8 million in cash and $183.3 million in equity, with no long-term debt.
•Revenue was $0 for Q3 FY2026.
•Net loss improved 17.7% year-over-year to $11.9 million.
•Operating loss improved 11.4% to $13.6 million.
•Cash and equivalents stood at $184.8 million with no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Benitec Biopharma Inc., a clinical-stage biotechnology company develops novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines. Its core technology is the Silence and Replace platform, a DNA-directed RNA interference (ddRNAi) approach that combines RNA interference with gene therapy. This platform aims to simultaneously silence disease-causing genes and deliver wildtype replacement genes after a single administration of the therapeutic construct. The company's lead product candidate is BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy (OPMD) related dysphagia. Benitec is headquartered in Hayward, California, and operates in the United States.
Where is Benitec Biopharma (BNTC) listed and what currency does it trade in?
Benitec Biopharma Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol BNTC. The company trades in US Dollars (USD), as it is headquartered in the United States and its primary listing is on a US exchange. The NasdaqCM is a market tier of the Nasdaq stock exchange that lists smaller-capitalization companies, providing them with access to public capital markets. Investors can buy and sell BNTC shares during regular trading hours on the NasdaqCM, and the stock is quoted in USD.
What sector and industry does Benitec Biopharma (BNTC) belong to?
Benitec Biopharma Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on using biological processes and genetic engineering to develop therapies. In particular, Benitec is a clinical-stage biotech firm, meaning it has not yet commercialized any products but is actively conducting clinical trials. Its work centers on genetic medicines, leveraging its proprietary Silence and Replace platform to create treatments for genetic disorders. The biotechnology industry is known for high research and development costs, long development timelines, and significant regulatory oversight, which are all relevant to Benitec's operations.
Where is Benitec Biopharma (BNTC) headquartered and what markets does it serve?
Benitec Biopharma Inc. is headquartered in Hayward, California, United States. The company primarily serves the US market, as indicated by its listing on a US exchange and its focus on developing therapies for conditions like oculopharyngeal muscular dystrophy (OPMD), which affects patients globally but has a significant presence in North America and Europe. While Benitec is a US-based company, its clinical-stage programs and potential future products could target international markets. However, based on the available data, the company's operations and headquarters are firmly in the United States, and it operates under US regulatory frameworks such as the FDA.